Terry Fox Research Institute Financial Statements

March 31, 2025

### **Terry Fox Research Institute** Contents For the year ended March 31, 2025

P	age
Independent Auditor's Report	
Financial Statements	
Statement of Financial Position	. 1
Statement of Operations	. 2
Statement of Changes in Net Assets	. 3
Statement of Cash Flows	. 4
Notes to the Financial Statements	. 5



To the Board of Directors of Terry Fox Research Institute:

#### Opinion

We have audited the financial statements of Terry Fox Research Institute (the "Institute"), which comprise the statement of financial position as at March 31, 2025, and the statements of operations, changes in net assets and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Institute as at March 31, 2025, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

#### **Basis for Opinion**

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Institute in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Institute's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Institute or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Institute's financial reporting process.



2200 - 1021 West Hastings Street, Vancouver BC, V6E 0C3 1.877.688.8408 T: 604.685.8408 F: 604.685.8594



#### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Institute's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Institute to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Vancouver, British Columbia

June 24, 2025

MNPLLP **Chartered Professional Accountants** 



## Terry Fox Research Institute Statement of Financial Position

As at March 31, 2025

	ne at maion on,	
	2025	2024
Assets		
Current		
Cash	863,647	9,875,406
Accounts receivable and other assets (Note 7)	8,641,447	3,677,367
	9,505,094	13,552,773
Capital assets (Note 4)	157,117	58,843
	9,662,211	13,611,616
Liabilities		
Current		
Accounts payable and accrued liabilities	3,510,573	4,007,085
Grants payable	132,500	3,696,970
Deferred contributions (Note 5)	3,830,625	3,912,663
	7,473,698	11,616,718
Economic dependence (Note 2)		
Commitments (Note 8)		
Net Assets		
Invested in capital assets	157,117	58,843
Unrestricted	2,031,396	1,936,055
	2,188,513	1,994,898
	9,662,211	13,611,616

Approved on behalf of the Board of Directors

Director

Director

# Terry Fox Research Institute Statement of Operations For the year ended March 31, 2025

	·	
	2025	2024
Revenue		
The Terry Fox Foundation contributions (Note 7)	24,463,000	21,179,000
Recognition of deferred contributions (Note 5), (Note 7)	40,728,884	26,212,782
Other research funding	100,000	100,000
Other income	364,274	418,330
	65,656,158	47,910,112
TFRI Programs		
Translational cancer research programs	410,661	1,079,992
Discovery programs	19,815,626	17,020,350
Research - other	397,713	275,000
Strategic & co-funded initiatives	1,381,226	714,258
Program operations	695,116	411,995
Marathon of Hope Cancer Centres Network	•	•
Building the cohort	35,073,377	23,507,865
Network training	1,099,600	796,125
Patient and health benefits	1,387,866	315,827
Network operations	1,553,545	1,206,717
Digital Health and Discovery Platform		
Platform development	1,132,603	200,000
Network operations	422,371	201,889
Data governance and policy	23,138	
	63,392,842	45,730,018
Administrative expenses (Note 6)	2,069,701	1,363,560
	65,462,543	47,093,578
Excess of revenue over expenses	193,615	816,534

# Terry Fox Research Institute Statement of Changes in Net Assets For the year ended March 31, 2025

	Invested in capital assets	Unrestricted	2025	2024
Balance, beginning of year	58,843	1,936,055	1,994,898	1,178,364
Excess (deficiency) of revenue over expenses	(27,944)	221,559	193,615	816,534
Investment in capital assets	126,218	(126,218)	-	_
Balance, end of year	157.117	2.031.396	2.188.513	1.994.898

#### Terry Fox Research Institute Statement of Cash Flows

For the year ended March 31, 2025

	2025	2024
Cash provided by (used for) the following activities		
Operating		
Excess of revenue over expenses	193,615	816,534
Amortization	27,944	31,374
	221,559	847,908
Changes in working capital accounts	,	011,000
Accounts receivable and other assets	(4,964,080)	(1,557,377)
Accounts payable and accrued liabilities	(496,512)	2,814,513
Grants payable	(3,564,470)	3,035,195
Deferred contributions	(82,038)	1,060,871
	(8,885,541)	6,201,110
Investing		
Purchase of capital assets	(126,218)	(17,676)
Increase (decrease) in cash resources	(9,011,759)	6,183,434
Cash, beginning of year	9,875,406	3,691,972
- acii, segiiiiiig ei jesi	0,010,400	0,001,012
Cash, end of year	863,647	9,875,406

## Terry Fox Research Institute Notes to the Financial Statements

For the year ended March 31, 2025

#### 1. General

The Terry Fox Research Institute (the "Institute") was incorporated by letters patent on March 14, 2007 to promote, advance and fund scientific research into the diagnosis, treatment and prevention of cancer. The Institute's mission is to provide grants to groups of researchers working toward a common cancer-related goal. The Institute also undertakes targeted programs supported by the Terry Fox Foundation and other external funders.

The Institute is a registered charitable organization under the Income Tax Act and, accordingly, is exempt from income taxes

The Terry Fox Foundation (the "Foundation"), a party related to the Institute with common members, raises funds for cancer research. Funds raised are provided to the Institute for allocation to cancer research chosen based upon excellence and the potential for impact. The Institute and the Foundation are maintained as separate and independent organizations with many common purposes and mutual interests.

The Institute has signed two major federal government contribution agreements with Health Canada and Innovation, Science, and Economic Development Canada ("ISED") toward the Marathon of Hope Cancer Centres (the "MOHCCN") and the Digital Health and Discovery Platform (the "DHDP") projects.

The MOHCCN is a pan-Canadian collaborative project that brings together the top cancer research centres across Canada to create a national network for collaborating cancer centres to accelerate precision medicine to propel discoveries and impact patient care in Canada.

The DHDP is a pan-Canadian project that brings together numerous private sector partners, public health institutions, not-for-profits, foundations, and charities to create and use a state-of-the-art digital health data sharing platform.

#### 2. Economic dependence

The Foundation provides significant funding to the Institute and the Institute remains economically dependent on the Foundation for significant future research commitments and operating funding.

#### 3. Significant accounting policies

These financial statements are prepared in accordance with Canadian accounting standards for not-for-profit organizations in Part III of the Chartered Professional Accountants of Canada Handbook - Accounting. The Institute's significant accounting policies are as follows:

#### Revenue recognition

The Institute follows the deferral method of accounting for contributions, which includes donations and government grants.

Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Externally restricted contributions are recognized as revenue in the year in which the related expenses are recognized.

Interest income on short-term investments is recorded on an accrual basis. Investment income generated by Health Canada funds is restricted and deferred for enhancing the MOHCCN project in future years.

## Terry Fox Research Institute Notes to the Financial Statements

For the year ended March 31, 2025

#### 3. Significant accounting policies (Continued from previous page)

#### Research and other expenses

Research expenses include research funding and the costs of managing research programs and networks. The Institute's research expenses (for translational and discovery projects, cancer centres, training and other projects) focuses on activities to advance the understanding, diagnosis and treatment of cancer with the goal of significantly improving the outcomes of cancer research for the patient. MOHCCN research expenses consist of grants to leading Canadian cancer research centres and other related projects with the aim of building and sharing a 15,000 cancer case data set. DHDP research expenses consist of grants that focus on building a shareable data platform driven by artificial intelligence, leading to novel research discoveries. Program operations and network operations include activities such as the scientific review processes, annual funding competitions, research forums, advisory committees, linkages with researchers, partnering and other project management salaries and contracted services.

The Institute recognizes a research grant expense when an approved research recipient has complied with the conditions of a research grant or collaborative research agreement and the Institute has approved payment of the research grant expense.

Other project management and operating expenses are recognized on the accrual basis of accounting.

#### Allocation of expenses

The Institute allocates a portion of its administrative expenses by identifying the appropriate allocation basis and applying that basis consistently each year. Administrative salaries are allocated on the basis of hours incurred related to each project.

#### Cash

Cash consists of short-term, highly liquid investments that are subject to insignificant changes in fair value, including cash on hand and deposits with financial institutions that can be withdrawn without prior notice. Cash is carried at cost, which approximates its fair value due to its short-term nature.

#### Financial instruments

Financial instruments are recorded at fair value on initial recognition and subsequently recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Institute has not elected to carry any such financial instruments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

#### Capital assets

Purchased capital assets are recorded at cost.

Amortization is provided using the straight-line method at rates intended to amortize the cost of assets over their estimated useful lives.

i cai s
3 years
5 years
5 years
5 years

#### 3. Significant accounting policies (Continued from previous page)

#### Use of estimates

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

#### Employee future benefits

Effective May 1, 2024, the Institute transitioned to a new defined contribution pension plan, DBPlus, administered by the Colleges of Applied Arts and Technology (CAAT) Pension Plan. Prior to this change, TFRI participated in a registered pension plan as an Affiliated Organization of the Registered Pension Plan for the Employees of the Canadian Cancer Society and Affiliated Organizations. As of May 1, 2024, the Registered Pension Plan for the Employees of the Canadian Cancer Society and Affiliated Organizations was formally terminated, and all eligible TFRI employees were transitioned to the CAAT DBPlus plan.

During the year, the Institute made employer contributions to the pension plans in the amount of \$175,167, which are recorded as operations expenses based on the respective employee's role, or as administrative expenses in accordance with the allocation of expenses policy.

#### 4. Capital assets

	Cost \$	Accumulated amortization	2025 Net book value \$	2024 Net book value \$
Computer equipment	80,794	54,879	25,915	12,369
Computer software	187,392	63,140	124,252	36,744
Furniture and fixtures	11,640	5,820	5,820	8,148
Leasehold improvements	2,260	1,130	1,130	1,582
	282,086	124,969	157,117	58,843

#### 5. Deferred contributions

Deferred contributions represent unspent grants or contract resources restricted for specific purposes and projects and include expenses for operating as well as capital purposes.

Health Canada will contribute to the MOHCCN up to \$150,000,000 over the term of the agreement provided that other funds are secured to match that contribution. In addition, contributions are also received from other foundations and sources to support match requirements.

ISED will contribute to the DHDP up to \$49,000,000 over the term of the agreement towards the total eligible project costs of \$132,500,000 incurred by the DHDP partners and the Institute.

#### 5. **Deferred contributions** (Continued from previous page)

Deferred contributions relating to expenses of future periods:

	Balance - March 31, 2024 \$	Current Year Contributions & Donations \$	Amounts Recognized as Revenue \$	Balance - March 31, 2025 \$
Marathon of Hope Cancer Centres Network	405.004	00 004 005	(00,000,000)	4 00- 04-
Health Canada	405,381	33,661,825	(33,039,290)	1,027,917
David & Dorothy Lam Foundation	311,750	100,000	(88,250)	323,500
The Terry Fox Foundation	3,040,045	5,364,105	(6,024,942)	2,379,208
Digital Health Discovery Platform				
Industry Science & Economic Development	55,486	1,520,916	(1,576,402)	-
The Terry Fox Foundation	100,000	-	-	100,000
-	3,912,663	40,646,846	(40,728,884)	3,830,625
Allocation of expenses				
			2025	2024
			\$	\$
Amortization			19,851	21,558
Communications			614,847	86,540
Compensation			1,093,811	898,424
Office space			49,236	59,083
Other admin			49,334	117,425
Professional fees			163,405	109,502
Travel			79,216	71,028
			2,069,700	1,363,560

Administrative expenses do not include research expenses allocated to program delivery costs or network operations. During the year, administrative compensation costs of \$249,813 (2024 - \$189,305) and amortization expenses of \$8,093 (2024 - \$9,816) have been allocated to the MOHCCN and the DHDP through network operations.

#### 7. Related party transactions

During the year, the Foundation provided the Institute with \$29,827,105 (2024 - \$23,087,711) in research funding, which included restricted funding of \$5,364,105 (2024 - \$1,908,711) towards future expenses under the MOHCCN project. During the year, the Institute distributed \$28,015,788 (2024 - \$19,089,600) to various institutions and partners for cancer research, and paid the Foundation \$428,775 (2024 - \$19,585) for payroll-related costs and other shared expenses. At the end of 2025, the Foundation owed the Institute \$210,018 (2024 - \$nil) related to restricted contributions, which was included in accounts receivable.

All related party transactions are in the normal course of operations and measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

#### 8. Commitments

The Institute has entered into a lease agreement for office premises in Vancouver that requires monthly base rent payments of \$4,804 until June 2025. Subsequent to year-end, this lease agreement was extended for one additional year. In August 2022, the Institute entered into a lease agreement for office premises in Montreal that requires monthly base rent payments of \$2,700 until March 2026 and is expected to renew after this date.

The Institute has also entered into a vendor agreement with a commitment to spend \$2 Million from January 2024 to March 2027 related to the DHDP Platform and eligible funded projects.

The Institute has committed to funding research projects over the next five years. The commitments are subject to availability of funds.

	Program project grants \$	New investigator awards \$	Strategic & co-funded initiatives \$	Other research \$	Marathon of Hope Cancer Centres Network \$	Digital Health and Discovery Platform \$	Total commitments \$
2026	16,372,691	2,265,508	1,686,668	312,500	13,623,429	675,000	34,935,796
2027	14,455,765	1,702,685	1,125,000	250,000	292,750	675,000	18,501,200
2028	8,928,283	661,938	1,125,000	250,000	54,250		11,019,471
2029	5,284,530	-	531,250	250,000	-	-	6,065,780
2030	851,929	-		250,000	-	-	1,101,929
_	45,893,198	4,630,131	4,467,918	1,312,500	13,970,429	1,350,000	71,624,176

#### 9. Financial instruments

The Institute, as part of its operations, carries a number of financial instruments. It is management's opinion that the Institute is not exposed to significant interest, currency, credit, liquidity or other price risks arising from these financial instruments except as otherwise disclosed.

#### Credit Risk

Credit risk is the risk of financial loss because a counter party to a financial instrument fails to discharge its contractual obligations. The Institute deals with government and other creditworthy counterparties to mitigate the risk of financial loss from defaults. The Institute is not exposed to significant credit risk.

#### Liquidity risk

Liquidity risk is the risk that the Institute will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Institute manages its liquidity risk by monitoring its operating requirements. The Institute prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations.